 | • レポートコード：MRC22iR11019 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、239ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品 |
| Single User | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Five User | ￥880,452 (USD5,949) | ▷ お問い合わせ |
| Enterprise License | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に4,378.75百万ドルであった世界の抗体薬物複合体市場規模が、2022年に5,076.28百万ドルになり、2027年まで年平均16.10%で成長して10,727.58百万ドルに達すると予測しています。本レポートでは、抗体薬物複合体の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場洞察、作用秩序別（CD30抗体、HER2抗体）分析、薬剤別（アドセトリス、カドサイラ）分析、技術別（切断型リンカー、リンカーレス、非切断型リンカー）分析、用途別（血液がん、乳がん、白血病、リンパ腫、多発性骨髄腫）分析、地域別（南北アメリカ、アジア太平洋、ヨーロッパ）分析、競争状況、企業情報などの項目を掲載しています。本書ではAbbvie Inc.、ADC Therapeutics、Agensys, Inc.、Astellas Pharma、AstraZeneca、Bayer AG、Celldex Therapeutics Inc.、Concortis Biotherapeutics、Daiichi Sankyo Company Ltd.、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、GlaxoSmithKline Plc、Immunomedics Inc.、Novartis AGなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場洞察 ・世界の抗体薬物複合体市場規模：作用秩序別 - CD30抗体の市場規模 - HER2抗体の市場規模 ・世界の抗体薬物複合体市場規模：薬剤別 - アドセトリスの市場規模 - カドサイラの市場規模 ・世界の抗体薬物複合体市場規模：技術別 - 切断型リンカー技術の市場規模 - リンカーレス技術の市場規模 - 非切断型リンカー技術の市場規模 ・世界の抗体薬物複合体市場規模：用途別 - 血液がんにおける市場規模 - 乳がんにおける市場規模 - 白血病における市場規模 - リンパ腫における市場規模 - 多発性骨髄腫における市場規模 ・世界の抗体薬物複合体市場規模：地域別 - 南北アメリカの抗体薬物複合体市場規模 - アジア太平洋の抗体薬物複合体市場規模 - ヨーロッパの抗体薬物複合体市場規模 ・競争状況 ・企業情報 |
The Global Antibody Drug Conjugate Market size was estimated at USD 4,378.75 million in 2021 and expected to reach USD 5,076.28 million in 2022, and is projected to grow at a CAGR 16.10% to reach USD 10,727.58 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Antibody Drug Conjugate to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Mechanism of Action, the market was studied across CD30 Antibodies and HER2 Antibodies.
Based on Drugs, the market was studied across Adcetris and Kadcyla.
Based on Technology, the market was studied across Cleavable Linker, Linkerless, and Non-cleavable Linker.
Based on Application, the market was studied across Blood Cancer, Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.
Based on End User, the market was studied across Academic Research Institutes, Biopharmaceutical Companies, Biotechnology Companies, Hospitals, Others, and Specialized Cancer Centers.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Antibody Drug Conjugate market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antibody Drug Conjugate Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antibody Drug Conjugate Market, including Abbvie Inc., ADC Therapeutics, Agensys, Inc., Astellas Pharma, AstraZeneca, Bayer AG, Celldex Therapeutics Inc., Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Immunomedics Inc., Novartis AG, Oxford BioTherapeutics, Pfizer, Inc., Sanofi S.A., Seagen, Inc., Seattle Genetics Inc., Synthon Holding B.V., and Takeda Pharmaceutical Company Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Antibody Drug Conjugate Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antibody Drug Conjugate Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antibody Drug Conjugate Market?
4. What is the competitive strategic window for opportunities in the Global Antibody Drug Conjugate Market?
5. What are the technology trends and regulatory frameworks in the Global Antibody Drug Conjugate Market?
6. What is the market share of the leading vendors in the Global Antibody Drug Conjugate Market?
7. What modes and strategic moves are considered suitable for entering the Global Antibody Drug Conjugate Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer worldwide
5.1.1.2. Growth in R&D activities and strong product pipeline
5.1.1.3. Surging geriatric population base
5.1.2. Restraints
5.1.2.1. High manufacturing cost of ADC
5.1.3. Opportunities
5.1.3.1. Increasing investment in biopharma R&D
5.1.3.2. Positive prospect in low market penetration nations
5.1.4. Challenges
5.1.4.1. Challenges related to downstream processing of Antibody Drug Conjugate
5.2. Cumulative Impact of COVID-19
6. Antibody Drug Conjugate Market, by Mechanism of Action
6.1. Introduction
6.2. CD30 Antibodies
6.3. HER2 Antibodies
7. Antibody Drug Conjugate Market, by Drugs
7.1. Introduction
7.2. Adcetris
7.3. Kadcyla
8. Antibody Drug Conjugate Market, by Technology
8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-cleavable Linker
9. Antibody Drug Conjugate Market, by Application
9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Leukemia
9.5. Lymphoma
9.6. Multiple Myeloma
9.7. Urothelial Cancer & Bladder Cancer
10. Antibody Drug Conjugate Market, by End User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical Companies
10.4. Biotechnology Companies
10.5. Hospitals
10.6. Others
10.7. Specialized Cancer Centers
11. Americas Antibody Drug Conjugate Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antibody Drug Conjugate Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antibody Drug Conjugate Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbvie Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. ADC Therapeutics
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Agensys, Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Astellas Pharma
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. AstraZeneca
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Bayer AG
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Celldex Therapeutics Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Concortis Biotherapeutics
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Daiichi Sankyo Company Ltd.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. F. Hoffmann-La Roche Ltd.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Gilead Sciences, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. GlaxoSmithKline Plc
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Immunomedics Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Novartis AG
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Oxford BioTherapeutics
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Pfizer, Inc.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Sanofi S.A.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Seagen, Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Seattle Genetics Inc.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Synthon Holding B.V.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. Takeda Pharmaceutical Company Ltd.
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
FIGURE 2. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2021 VS 2027
FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2021 VS 2027 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2027
FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2021 VS 2027 (%)
FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2021 VS 2027 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY MECHANISM OF ACTION, 2027
FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, 2018-2027 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HER2 ANTIBODIES, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2021 VS 2027 (%)
FIGURE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2021 VS 2027 (USD MILLION)
FIGURE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUGS, 2027
FIGURE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, 2018-2027 (USD MILLION)
FIGURE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, 2018-2027 (USD MILLION)
FIGURE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (%)
FIGURE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (USD MILLION)
FIGURE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY, 2027
FIGURE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, 2018-2027 (USD MILLION)
FIGURE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, 2018-2027 (USD MILLION)
FIGURE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, 2018-2027 (USD MILLION)
FIGURE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, 2018-2027 (USD MILLION)
FIGURE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, 2018-2027 (USD MILLION)
FIGURE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LEUKEMIA, 2018-2027 (USD MILLION)
FIGURE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, 2018-2027 (USD MILLION)
FIGURE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2027 (USD MILLION)
FIGURE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, 2018-2027 (USD MILLION)
FIGURE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2021 VS 2027 (USD MILLION)
FIGURE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2027
FIGURE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2027 (USD MILLION)
FIGURE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2027 (USD MILLION)
FIGURE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2027 (USD MILLION)
FIGURE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2027 (USD MILLION)
FIGURE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY OTHERS, 2018-2027 (USD MILLION)
FIGURE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, 2018-2027 (USD MILLION)
FIGURE 45. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 47. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 48. AMERICAS ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 49. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 55. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 56. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 57. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 59. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 60. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 61. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 62. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 65. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 66. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 67. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 68. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 69. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 70. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 71. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 72. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 73. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 74. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 75. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD MILLION)
FIGURE 76. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2027
FIGURE 77. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 78. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 79. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 80. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 81. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 82. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 83. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 84. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 85. NIGERIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 86. NORWAY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 87. POLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 88. QATAR ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 89. RUSSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 90. SAUDI ARABIA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 91. SOUTH AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 92. SPAIN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 93. SWEDEN ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 94. SWITZERLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 95. TURKEY ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 96. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 97. UNITED KINGDOM ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 98. GLOBAL ANTIBODY DRUG CONJUGATE MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 99. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 100. GLOBAL ANTIBODY DRUG CONJUGATE MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021